{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:57:38Z","timestamp":1781225858654,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40256-026-00790-z","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T06:49:35Z","timestamp":1771224575000},"page":"383-389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining the Role of Intravenous Iron in The Treatment of Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-3549","authenticated-orcid":false,"given":"Andrew","family":"Sephien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea","family":"Reljic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea","family":"Sancassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason N.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"1","key":"790_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","volume":"31","author":"B Bozkurt","year":"2025","unstructured":"Bozkurt B, Ahmad T, Alexander K, Baker WL, Bosak K, Breathett K, et al. HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the Heart Failure Society of America. J Card Fail. 2025;31(1):66\u2013116.","journal-title":"J Card Fail"},{"issue":"4","key":"790_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","volume":"165","author":"IT Klip","year":"2013","unstructured":"Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-82e3.","journal-title":"Am Heart J"},{"key":"790_CR3","unstructured":"Organization WH. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. 2011."},{"issue":"19","key":"790_CR4","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1056\/NEJMra1401038","volume":"372","author":"C Camaschella","year":"2015","unstructured":"Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832\u201343.","journal-title":"N Engl J Med"},{"key":"790_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000759","author":"A Kumar","year":"2022","unstructured":"Kumar A, Sharma E, Marley A, Samaan MA, Brookes MJ. Iron deficiency anaemia: pathophysiology, assessment, practical management. BMJ Open Gastroenterol. 2022. https:\/\/doi.org\/10.1136\/bmjgast-2021-000759.","journal-title":"BMJ Open Gastroenterol"},{"issue":"12","key":"790_CR6","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/ejhf.1305","volume":"20","author":"T McDonagh","year":"2018","unstructured":"McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P, et al. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. Eur J Heart Fail. 2018;20(12):1664\u201372.","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"790_CR7","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032.","journal-title":"Circulation"},{"issue":"36","key":"790_CR8","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"11","key":"790_CR9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.cardfail.2011.08.003","volume":"17","author":"EA Jankowska","year":"2011","unstructured":"Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail. 2011;17(11):899\u2013906.","journal-title":"J Card Fail"},{"issue":"10","key":"790_CR10","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/ejhf.161","volume":"16","author":"TJ Yeo","year":"2014","unstructured":"Yeo TJ, Yeo PS, Ching-Chiew Wong R, Ong HY, Leong KT, Jaufeerally F, et al. Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail. 2014;16(10):1125\u201332.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"790_CR11","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/ejhf.1202","volume":"20","author":"A Iorio","year":"2018","unstructured":"Iorio A, Senni M, Barbati G, Greene SJ, Poli S, Zambon E, et al. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. Eur J Heart Fail. 2018;20(9):1257\u201366.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"790_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","volume":"26","author":"TA McDonagh","year":"2024","unstructured":"Authors\/Task Force M, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2024;26(1):5\u201317.","journal-title":"Eur J Heart Fail"},{"key":"790_CR13","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1038\/s41591-025-03671-1","volume":"31","author":"SD Anker","year":"2025","unstructured":"Anker SD, Karakas M, Mentz RJ, Ponikowski P, Butler J, Khan MS, et al. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med. 2025;31:2640\u20136.","journal-title":"Nat Med"},{"issue":"2","key":"790_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40256-024-00635-7","volume":"24","author":"A Sephien","year":"2024","unstructured":"Sephien A, Dayto DC, Reljic T, Prida X, Joly JM, Tavares M, et al. Efficacy of intravenous iron in patients with heart failure with reduced ejection fraction and iron deficiency: a systematic review and meta-analysis of randomized control trials. Am J Cardiovasc Drugs. 2024;24(2):285\u2013302.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"790_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004519","volume":"11","author":"N Grote Beverborg","year":"2018","unstructured":"Grote Beverborg N, Klip IT, Meijers WC, Voors AA, Vegter EL, van der Wal HH, et al. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ Heart Fail. 2018;11(2):e004519.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"790_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","volume":"79","author":"G Masini","year":"2022","unstructured":"Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, et al. Criteria for iron deficiency in patients with heart failure. J Am Coll Cardiol. 2022;79(4):341\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"790_CR17","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1161\/CIRCULATIONAHA.113.006588","volume":"130","author":"JM Stolker","year":"2014","unstructured":"Stolker JM, Spertus JA, Cohen DJ, Jones PG, Jain KK, Bamberger E, et al. Rethinking composite end points in clinical trials: insights from patients and trialists. Circulation. 2014;130(15):1254\u201361.","journal-title":"Circulation"},{"issue":"4","key":"790_CR18","doi-asserted-by":"publisher","DOI":"10.31083\/RCM28216","volume":"26","author":"HP Sung","year":"2025","unstructured":"Sung HP, Yin WH, Chen SF, Hung CL, Lin KC, Chang HY. Intravenous iron sucrose for acute decompensated heart failure patients with reduced ejection fraction and iron deficiency. Rev Cardiovasc Med. 2025;26(4):28216.","journal-title":"Rev Cardiovasc Med"},{"issue":"22","key":"790_CR19","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1001\/jama.2025.3833","volume":"333","author":"SD Anker","year":"2025","unstructured":"Anker SD, Friede T, Butler J, Talha KM, Placzek M, Diek M, et al. Intravenous ferric carboxymaltose in heart failure with iron deficiency: the FAIR-HF2 DZHK05 randomized clinical trial. JAMA. 2025;333(22):1965\u201376.","journal-title":"JAMA"},{"issue":"11","key":"790_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","volume":"389","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, et al. Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med. 2023;389(11):975\u201386.","journal-title":"N Engl J Med"},{"issue":"10266","key":"790_CR21","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895\u2013904.","journal-title":"Lancet"},{"issue":"11","key":"790_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657\u201368.","journal-title":"Eur Heart J"},{"issue":"48","key":"790_CR23","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1093\/eurheartj\/ehad586","volume":"44","author":"P Ponikowski","year":"2023","unstructured":"Ponikowski P, Mentz RJ, Hernandez AF, Butler J, Khan MS, van Veldhuisen DJ, et al. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Eur Heart J. 2023;44(48):5077\u201391.","journal-title":"Eur Heart J"},{"issue":"25","key":"790_CR24","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"790_CR25","doi-asserted-by":"publisher","first-page":"Fso467","DOI":"10.2144\/fsoa-2019-0156","volume":"6","author":"S Dhoot","year":"2020","unstructured":"Dhoot S, Mittal S, Singh SP, Patel V, Kasliwal RR, Mehta V. Effect of ferric-carboxy maltose on oxygen kinetics and functional status in heart failure patients with iron deficiency. Future Sci OA. 2020;6(5):Fso467.","journal-title":"Future Sci OA."},{"issue":"15","key":"790_CR26","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","volume":"136","author":"DJ van Veldhuisen","year":"2017","unstructured":"van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bohm M, Doletsky A, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136(15):1374\u201383.","journal-title":"Circulation"},{"issue":"4","key":"790_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014254","volume":"9","author":"J Nunez","year":"2020","unstructured":"Nunez J, Minana G, Cardells I, Palau P, Llacer P, Facila L, et al. Noninvasive imaging estimation of myocardial iron repletion following administration of intravenous iron: the Myocardial-IRON Trial. J Am Heart Assoc. 2020;9(4):e014254.","journal-title":"J Am Heart Assoc"},{"key":"790_CR28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/suz157","volume":"21","author":"M Karakas","year":"2019","unstructured":"Karakas M. Effect of ferric carboxymaltose on LVEF as assessed by cardiac MRI in patients with chronic heart failure and iron deficiency: a randomized, double-blinded, placebo-controlled, dual-center trial. Eur J Heart Fail. 2019;21:176.","journal-title":"Eur J Heart Fail"},{"issue":"48","key":"790_CR29","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1093\/eurheartj\/ehab411","volume":"42","author":"P Martens","year":"2021","unstructured":"Martens P, Dupont M, Dauw J, Nijst P, Herbots L, Dendale P, et al. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial. Eur Heart J. 2021;42(48):4905\u201314.","journal-title":"Eur Heart J"},{"issue":"4","key":"790_CR30","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1016\/j.ijcard.2013.04.181","volume":"168","author":"L Beck-da-Silva","year":"2013","unstructured":"Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol. 2013;168(4):3439\u201342.","journal-title":"Int J Cardiol"},{"issue":"17","key":"790_CR31","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","volume":"50","author":"JE Toblli","year":"2007","unstructured":"Toblli JE, Lombra\u00f1a A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50(17):1657\u201365.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"790_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","volume":"51","author":"DO Okonko","year":"2008","unstructured":"Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51(2):103\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"790_CR33","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/eurheartj\/ehx493.P5825","volume":"38","author":"G Youssef","year":"2017","unstructured":"Youssef G, Kamal A, Diab R, Abdel HM. Intravenous iron therapy in acute decompensated heart failure patients with iron deficiency anaemia. Eur Heart J. 2017;38:1231.","journal-title":"Eur Heart J"},{"key":"790_CR34","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2022","unstructured":"Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400:2199\u2013209.","journal-title":"Lancet"},{"issue":"21","key":"790_CR35","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1161\/CIRCULATIONAHA.118.038516","volume":"139","author":"G Charles-Edwards","year":"2019","unstructured":"Charles-Edwards G, Amaral N, Sleigh A, Ayis S, Catibog N, McDonagh T, et al. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency. Circulation. 2019;139(21):2386\u201398.","journal-title":"Circulation"},{"key":"790_CR36","unstructured":"Daiichi Sankyo I. About Injectafer\u00ae (ferric carboxymaltose injection). 2024 [cited July 16, 2025]. https:\/\/injectaferhcp.com\/about-injectafer."},{"issue":"8","key":"790_CR37","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/ejhf.2879","volume":"25","author":"F Lindberg","year":"2023","unstructured":"Lindberg F, Lund LH, Benson L, Linde C, Orsini N, Carrero JJ, et al. Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborative project. Eur J Heart Fail. 2023;25(8):1270\u201380.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"790_CR38","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/ehf2.13245","volume":"8","author":"T Pezel","year":"2021","unstructured":"Pezel T, Audureau E, Mansourati J, Baudry G, Ben Driss A, Durup F, et al. Diagnosis and treatment of iron deficiency in heart failure: OFICSel study by the French Heart Failure Working Group. ESC Heart Fail. 2021;8(2):1509\u201321.","journal-title":"ESC Heart Fail."},{"issue":"1","key":"790_CR39","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/ejhf.3356","volume":"27","author":"M Camilli","year":"2025","unstructured":"Camilli M, Ballacci F, Rossi VA, Cannata A, Monzo L, Mewton N, et al. Iron deficiency and supplementation in patients with heart failure: results from the IRON-HF international survey. Eur J Heart Fail. 2025;27(1):140\u20137.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"790_CR40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/jac5.2081","volume":"8","author":"J Alaryani","year":"2025","unstructured":"Alaryani J, Manla Y, Abidi E, Kholoki O, Hisham M, Al Badarin F, et al. Screening and treatment of iron deficiency among heart failure patients with impaired ejection fraction: the impact of a pharmacist\u2010led protocol. JACCP J Am Coll Clin Pharm. 2025;8(3):182\u201391.","journal-title":"JACCP J Am Coll Clin Pharm"},{"issue":"Suppl_1","key":"790_CR41","doi-asserted-by":"publisher","first-page":"A17875-A","DOI":"10.1161\/circ.148.suppl_1.17875","volume":"148","author":"RS Jakulla","year":"2023","unstructured":"Jakulla RS, Fatima I, Gunta P, Gill K, Mohammed MS, Elsayed M, et al. Quality improvement initiative to improve screening and diagnosis rates of iron deficiency in patients hospitalized for acute heart failure with reduced ejection fraction. Circulation. 2023;148(Suppl_1):A17875-A.","journal-title":"Circulation"},{"issue":"13","key":"790_CR42","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","volume":"146","author":"KF Docherty","year":"2022","unstructured":"Docherty KF, Welsh P, Verma S, De Boer RA, O\u2019Meara E, Bengtsson O, et al. Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation. 2022;146(13):980\u201394.","journal-title":"Circulation"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00790-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00790-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00790-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:03:31Z","timestamp":1781222611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00790-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00790-z","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew Sephien, Tea Reljic, Rhea Sancassani, Joanna M. Joly, and Ambuj Kumar declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.\u00a0Jason N. Katz has speaking roles for Zoll and Abiomed\/Johnson & Johnson and receives modest honoraria.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Andrew Sephien\n                      : conceptualization, analysis, writing, reviewing and editing;\n                      Tea Reljic\n                      : conceptualization, analysis, reviewing and editing;\n                      Rhea Sancassani\n                      : conceptualization, reviewing and editing;\n                      Joanna M. Joly\n                      : conceptualization, reviewing and editing;\n                      Jason N. Katz\n                      : conceptualization, reviewing and editing;\n                      Ambuj Kumar\n                      : conceptualization, supervision, analysis, reviewing and editing","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"Data sharing not applicable to this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}